Production (Stage)
Purple Biotech Ltd
PPBT
$2.61
-$0.09-3.33%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -68.37% | -- | -- | 63.33% | |
| Gross Profit | 68.37% | -- | -- | -63.33% | |
| SG&A Expenses | -40.17% | -39.51% | -35.78% | -45.67% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -83.79% | -36.59% | -12.81% | -3.08% | |
| Operating Income | 83.79% | 36.59% | 12.81% | 3.08% | |
| Income Before Tax | 91.46% | 53.20% | 22.88% | 19.59% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 91.46% | 53.20% | 22.88% | 19.59% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -83.87% | -54.55% | -24.00% | -3.13% | |
| Net Income | 91.51% | 53.19% | 22.88% | 19.68% | |
| EBIT | 83.79% | 36.59% | 12.81% | 3.08% | |
| EBITDA | 83.89% | 36.89% | 12.96% | 2.50% | |
| EPS Basic | 94.65% | 64.49% | -11,180.49% | 42.81% | |
| Normalized Basic EPS | 94.87% | 67.11% | -- | 41.21% | |
| EPS Diluted | 94.71% | 64.49% | -11,180.49% | 42.20% | |
| Normalized Diluted EPS | 94.87% | 67.11% | -- | 41.21% | |
| Average Basic Shares Outstanding | 59.08% | 31.07% | -99.32% | 40.24% | |
| Average Diluted Shares Outstanding | 59.08% | 31.07% | -99.32% | 40.24% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |